Monday, October 6, 2014

Cannabics Pharmaceuticals Inc. (CNBX) Putting Bio-technology in a Blooming Traditional Industry

It’s common knowledge that law tends to trail technology and social movements, sometimes by years, sometimes by decades. The process of getting new ideas codified in clear and workable legislation can be a long and arduous path, often spotted with periods of contradictory or inconsistently enforced regulations. Nevertheless, after a certain amount of trial and error, the dust eventually settles, issues get clarified, and real changes can take effect.

The mounting pressure to allow the use of cannabinoids for the palliative treatment of patients with cancer and other diseases has begun to open the door to a multi-billion dollar market in the U.S., also potentially generating billions in tax revenue. The amount of money involved in all this has led to contentious ballot measures at state and city levels throughout the country, with increasing degrees of legalization expected to be pushed through for years to come.

Although the legalization of recreational marijuana is in the sites of various activist groups, by far the most wide-spread support continues to focus on cannabinoids for medical use. And it’s not just for cancer. A number of painful and debilitating diseases are now considered targets for the use of medical cannabis. For example, according to a recent report in silive.com (http://dtn.fm/8HtB), both U.S. senators from New York have called on the Department of Justice to allow for the speed up of the state’s new medical marijuana dispensing program for children experiencing epilepsy and other seizure disorders.

However, in spite of the fact that marijuana has already established itself as a major industry in California and elsewhere, it’s an industry that is still largely unorganized and fragmented. As a result, there remain huge quality and information gaps, a mounting problem for new patients who are used to dealing with the medical establishment. The lack of modern controlled research and product development has hampered progress. Still, for some companies, this has represented a unique opportunity.

Cannabics Pharmaceuticals Inc. has been working to introduce much needed technology and control to the development of cannabinoid based products. Interestingly, the company itself does not manufacture, distribute, or dispense any controlled substances. Rather it develops proprietary technologies that are then licensed for use by certified and governmentally approved manufacturers and distributors. Their goal is the scientific determination of efficacy for various cannabis strains as therapies for specific indications, along with the best administration routes for active cannabinoids, something severely lacking in the U.S. medical cannabis industry since regulation essentially halted it nearly a century ago.

The company has already formulated carefully-researched Cannabics SR Capsules targeting cancer patients, and has achieved Good Manufacturing Practices (GMP) capabilities in preparation for its first clinical study of the capsules. Adhering to these practices ranks the company’s products among a very limited number of medical cannabis products available in the U.S. market that are manufactured according to GMP standards.

For more information, visit www.cannabics.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net


Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: